Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Northern Europe has been on the rise in recent years.
Customer preferences: Patients in Northern Europe are increasingly opting for Anti-Rheumatic Drugs due to the rising prevalence of rheumatoid arthritis and other autoimmune diseases. The preference for biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs) has also been increasing due to their higher efficacy and lower toxicity.
Trends in the market: The Anti-Rheumatic Drugs market in Northern Europe is witnessing a shift towards biosimilars due to their lower cost as compared to biologics. The availability of biosimilars has increased competition in the market, leading to a decrease in prices. This has made Anti-Rheumatic Drugs more accessible to patients in the region. Additionally, there has been a rise in the use of combination therapies, which involve the use of multiple drugs to achieve better outcomes.
Local special circumstances: In Norway and Denmark, the government has implemented policies to promote the use of biosimilars. This has led to a higher adoption rate of biosimilars in these countries. In Sweden, the government has implemented a national rheumatology quality register, which has led to improved patient outcomes and increased demand for Anti-Rheumatic Drugs.
Underlying macroeconomic factors: The aging population in Northern Europe has contributed to the rising prevalence of rheumatoid arthritis and other autoimmune diseases. Additionally, the increasing healthcare expenditure in the region has led to improved access to healthcare services, including the availability of Anti-Rheumatic Drugs. The ongoing COVID-19 pandemic has also led to an increased demand for Anti-Rheumatic Drugs, as patients with autoimmune diseases are at a higher risk of severe illness from COVID-19.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
